116 related articles for article (PubMed ID: 7741988)
21. Development of new immunoradiometric assay for CA 125 antigen using two monoclonal antibodies produced by immunizing lung cancer cells.
Kunimatsu M; Endo K; Nakashima T; Awaji T; Saga T; Watanabe Y; Kawamura Y; Ohta H; Koizumi M; Sakahara H
Ann Nucl Med; 1988 Nov; 2(2):73-9. PubMed ID: 3275111
[TBL] [Abstract][Full Text] [Related]
22. How to overcome the disturbing effects of human anti-mouse antibodies (HAMA) on in vitro assays.
Oltrogge JB; Baum RP; Lema KN; Donnerstag B; Hör G
Int J Biol Markers; 1997; 12(1):15-7. PubMed ID: 9176712
[TBL] [Abstract][Full Text] [Related]
23. CA 125 in gynecological pathology--a review.
Kenemans P; Yedema CA; Bon GG; von Mensdorff-Pouilly S
Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):115-24. PubMed ID: 8365505
[TBL] [Abstract][Full Text] [Related]
24. Time-resolved immunofluorometric assay for the ovarian carcinoma-associated antigenic determinant CA 125 in serum.
Boerman OC; Thomas CM; Segers MF; Kenemans P; Lövgren T; Zurawski VR; Haisma HJ; Poels LG
Clin Chem; 1987 Dec; 33(12):2191-4. PubMed ID: 2446805
[TBL] [Abstract][Full Text] [Related]
25. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen.
Blijenberg BG; Eman I; Boevé ER; Mössner E; Uhl W
Eur J Clin Chem Clin Biochem; 1995 Jun; 33(6):383-92. PubMed ID: 7578619
[TBL] [Abstract][Full Text] [Related]
26. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
27. Ultrasensitive bioassay of epitope of Mucin-16 protein (CA 125) in human plasma samples using a novel immunoassay based on silver conductive nano-ink: A new platform in early stage diagnosis of ovarian cancer and efficient management.
Jafari M; Hasanzadeh M; Solhi E; Hassanpour S; Shadjou N; Mokhtarzadeh A; Jouyban A; Mahboob S
Int J Biol Macromol; 2019 Apr; 126():1255-1265. PubMed ID: 30615961
[TBL] [Abstract][Full Text] [Related]
28. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
29. Technical and clinical comparison of two fully automated methods for the immunoassay of CA 125 in serum.
Yan G; Ju H; Liang Z; Zhang T
J Immunol Methods; 1999 May; 225(1-2):1-8. PubMed ID: 10365777
[TBL] [Abstract][Full Text] [Related]
30. A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer.
Risum S; Høgdall E; Engelholm SA; Fung E; Lomas L; Yip C; Petri AL; Nedergaard L; Lundvall L; Høgdall C
Int J Gynecol Cancer; 2009 Dec; 19(9):1535-8. PubMed ID: 19955932
[TBL] [Abstract][Full Text] [Related]
31. Comparison of an immunoradiometric and an immunoluminometric assay for the evaluation of the tumour associated antigens CA 19-9 and CA 125.
Mader RM; Steger GG; Braun J; Rainer H
Eur J Clin Chem Clin Biochem; 1994 Feb; 32(2):85-90. PubMed ID: 8003582
[TBL] [Abstract][Full Text] [Related]
32. CA 125: fundamental and clinical aspects.
Verheijen RH; von Mensdorff-Pouilly S; van Kamp GJ; Kenemans P
Semin Cancer Biol; 1999 Apr; 9(2):117-24. PubMed ID: 10202133
[TBL] [Abstract][Full Text] [Related]
33. Markers supplementing CA 125 in ovarian cancer.
Stenman UH; Alfthan H; Vartiainen J; Lehtovirta P
Ann Med; 1995 Feb; 27(1):115-20. PubMed ID: 7741989
[TBL] [Abstract][Full Text] [Related]
34. Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System.
Holdenrieder S; Molina R; Gion M; Gressner A; Troalen F; Auge JM; Zancan M; Wycislo M; Stieber P
Clin Chem Lab Med; 2008; 46(5):588-99. PubMed ID: 18598201
[TBL] [Abstract][Full Text] [Related]
35. [Usefulness of CA-125 antigen for monitoring neoplastic processes in patients with ovarian tumors].
Kwaśniewska-Rokicińska C; Bartnikowa W; Koterbicka A; Deja R
Ginekol Pol; 1994 Mar; 65(3):136-41. PubMed ID: 8001848
[No Abstract] [Full Text] [Related]
36. The role of ultrasound and tumour markers in the early detection of ovarian cancer.
Oram DH; Jeyarajah AR
Br J Obstet Gynaecol; 1994 Nov; 101(11):939-45. PubMed ID: 7999723
[No Abstract] [Full Text] [Related]
37. Ultrasensitive immunoassay of carcinoma antigen 125 in untreated human plasma samples using gold nanoparticles with flower like morphology: A new platform in early stage diagnosis of ovarian cancer and efficient management.
Hasanzadeh M; Sahmani R; Solhi E; Mokhtarzadeh A; Shadjou N; Mahboob S
Int J Biol Macromol; 2018 Nov; 119():913-925. PubMed ID: 30081127
[TBL] [Abstract][Full Text] [Related]
38. Quantification of MUC1 in breast cancer patients. A method comparison study.
Bon GG; van Kamp GJ; Verstraeten RA; von Mensdorff-Pouilly S; Hilgers J; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1999 Mar; 83(1):67-75. PubMed ID: 10221613
[TBL] [Abstract][Full Text] [Related]
39. How CA 125 is used in routine clinical practice.
Petignat P; Joris F; Obrist R
Eur J Cancer; 2000 Oct; 36(15):1933-7. PubMed ID: 11000573
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
Mrochem J; Sodowski K; Deja R; Walaszek-Gruszka A; Wojcieszek A; Kołosza Z; Chmura A; Czernik E; Masłyk B; Bartnik W; Cnota W
Ginekol Pol; 2008 Apr; 79(4):271-5. PubMed ID: 18592865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
